These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18452071)

  • 41. Laryngeal involvement by mycosis fungoides.
    Ferlito A; Recher G
    Ann Otol Rhinol Laryngol; 1986; 95(3 Pt 1):275-7. PubMed ID: 3717853
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy.
    Rawstron AC; Laycock-Brown G; Hale G; Davies FE; Morgan GJ; Child JA; Hillmen P; Owen RG
    Haematologica; 2006 Nov; 91(11):1577-8. PubMed ID: 17043027
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Measuring humanized antibodies in plasma of patients treated with antibody-based therapy using bead-based flow cytometry: the story of alemtuzumab.
    Chan HE; Jilani I; Chang R; Albitar M
    Methods Mol Biol; 2007; 378():159-65. PubMed ID: 18605084
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis.
    Thompson B; Corris P; Miller JA; Cooper RG; Halsey JP; Isaacs JD
    J Rheumatol; 2008 Oct; 35(10):2080-2. PubMed ID: 18843768
    [No Abstract]   [Full Text] [Related]  

  • 45. Alemtuzumab.
    Weaver TA; Kirk AD
    Transplantation; 2007 Dec; 84(12):1545-7. PubMed ID: 18165760
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab: prophylaxis vs. pre-emptive strategies for prevention.
    Worth LJ; Thursky KA
    Leuk Lymphoma; 2006 Dec; 47(12):2435-6. PubMed ID: 17169785
    [No Abstract]   [Full Text] [Related]  

  • 47. Ocular and cerebral aspergillosis in a non-neutropenic patient following alemtuzumab and methyl prednisolone treatment for chronic lymphocytic leukaemia.
    Anoop P; Stanford M; Saso R; Dearden CE
    J Infect Chemother; 2010 Apr; 16(2):150-1. PubMed ID: 20108019
    [No Abstract]   [Full Text] [Related]  

  • 48. Purely follicular mycosis fungoides without mucinosis: report of two cases with review of the literature.
    Monopoli A; Annessi G; Lombardo GA; Baliva G; Girolomoni G
    J Am Acad Dermatol; 2003 Mar; 48(3):448-52. PubMed ID: 12637929
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dermatopathic lymphadenopathy. An immunophenotypic comparison of cases associated and unassociated with mycosis fungoides.
    Burke JS; Sheibani K; Rappaport H
    Am J Pathol; 1986 May; 123(2):256-63. PubMed ID: 3486598
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab.
    Chu D; Stevens M; Gladstone DE
    Rheumatol Int; 2007 Oct; 27(12):1173-5. PubMed ID: 17443327
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Leonine facies (LF) and mycosis fungoides (MF): A single-center study and systematic review of the literature.
    Brown DN; Wieser I; Wang C; Dabaja BS; Duvic M
    J Am Acad Dermatol; 2015 Dec; 73(6):976-86. PubMed ID: 26476898
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
    Lush RJ; Haynes AP; Byrne J; Cull GM; Carter GI; Pagliuca A; Parker JE; Mufti G; Mahendra P; Craddock CF; Lui Yin JA; Garg M; Prentice HG; Potter MN; Russell NH
    Cytotherapy; 2001; 3(3):203-10. PubMed ID: 12171727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).
    Thieblemont C; Bouafia F; Hornez E; Dumontet C; Tartas S; Antal D; Lemieux B; Traullé C; Espinouse D; Salles G; Coiffier B
    Leuk Lymphoma; 2004 Apr; 45(4):711-4. PubMed ID: 15160944
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Alemtuzumab and multiple sclerosis].
    Nau JY
    Rev Med Suisse; 2008 Nov; 4(178):2425. PubMed ID: 19051633
    [No Abstract]   [Full Text] [Related]  

  • 55. Alemtuzumab in the reversal of encephalopathy associated with hypereosinophilic syndrome.
    Perini GF; Santos FP; Hamerschlak N
    Br J Haematol; 2009 Dec; 147(5):592. PubMed ID: 19545288
    [No Abstract]   [Full Text] [Related]  

  • 56. A case of CD56+ mycosis fungoides.
    Klekotka PA; Faulkner-Jones B; Heffernan MP
    Arch Dermatol; 2006 Oct; 142(10):1370-2. PubMed ID: 17043207
    [No Abstract]   [Full Text] [Related]  

  • 57. Successful use of alemtuzumab in a child with refractory peripheral T-cell posttransplant lymphoproliferative disorder.
    Bartakke S; Abla O; Weitzman S
    J Pediatr Hematol Oncol; 2008 Oct; 30(10):787-8. PubMed ID: 19011483
    [No Abstract]   [Full Text] [Related]  

  • 58. Clinical case of the month. A young man with a persistent skin eruption. Mycosis fungoides.
    Kendrick CG; Gerdes MS; Lopez FA; McBurney EI
    J La State Med Soc; 2004; 156(2):73-7. PubMed ID: 15106864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alemtuzumab: what is the secret to safe therapy?
    Elter T; Hallek M; Montillo M
    Clin Adv Hematol Oncol; 2011 May; 9(5):364-73. PubMed ID: 21685865
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mycosis fungoides? Sezary syndrome.
    Roenigk HH; Taylor JG
    Arch Dermatol; 1970 Feb; 101(2):244-6. PubMed ID: 4244178
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.